MIEF2

Across TCGA pan-cancer cohorts, MIEF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MIEF2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MIEF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIEF2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LSCC, and GBM are the cancer types where MIEF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.259	.036	12	view →
LSCC	DFS	Tertile	All	0.604	1.000	.025	5	view →
GBM	OS	Tertile	All	0.793	0.383	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MIEF2–HNSC (DFS)

Open the HNSC breakdown →